Physician profile
Murali M Chakinala
NPI 1407872724
$172,235.02
in general payments reported to CMS, 2019-2025
18 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $21K · 2021: $5,369 · 2022: $15K · 2023: $22K · 2024: $51K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $87K · Travel and Lodging: $19K · Food and Beverage: $6,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $87,166.00 |
| Travel and Lodging | $19,419.30 |
| Food and Beverage | $6,260.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53,692.17 | 2019-2025 | Winrevair, Keytruda |
| United Therapeutics Corporation | $42,739.26 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Actelion Pharmaceuticals US, INC. | $26,241.54 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $20,464.49 | 2019-2025 | |
| Actelion Pharmaceuticals, Ltd | $8,498.01 | 2019-2020 | |
| Insmed, INC. | $7,200.17 | 2022-2025 | |
| Chiesi USA, INC. | $5,474.52 | 2025 | |
| Janssen Scientific Affairs, LLC | $5,375.00 | 2024 | Uptravi |
| Alnylam Pharmaceuticals INC. | $1,627.93 | 2025 | |
| Sandoz INC. | $613.71 | 2019-2025 | Treprostinil |
| Liquidia Technologies, INC. | $140.41 | 2025 | Yutrepia |
| Penumbra, INC. | $135.67 | 2025 | Indigo System |
| Astrazeneca Pharmaceuticals Lp | $18.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.75 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murali Chakinala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.